Back to top

Image: Bigstock

PerkinElmer, Inc.

Read MoreHide Full Article

PerkinElmer outperformed its industry in the past year. A number of product launches resulted in solid organic revenue growth for the company. Furthermore, a positive guidance instills our confidence in the stock. PerkinElmer’s strong global foothold is noteworthy, courtesy of its acquisition of Germany-based EUROIMMUN and India-based Tulip Diagnostics. EUROIMMUN acquisition has significantly expanded PerkinElmer’s reach into autoimmune and allergy diagnostic markets. With an enhanced focus on product innovation, PerkinElmer has considerable potential upside. On the flipside, despite having a diversified portfolio, unfavorable foreign exchange is a primary concern. PerkinElmer continues to acquire a large number of companies which adds integration risks. Also, high debt levels may hinder the company’s expansion plans.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


PerkinElmer, Inc. (PKI) - free report >>

Published in